116850-44-3

Basic information

• Product Name: 4-methyl-3-methylsulfonyl-5-phenyl-1,2,4-triazole
• Synonyms: 4-methyl-3-methylsulfonyl-5-phenyl-1,2,4-triazole;MDL 27531;3-methanesulfonyl-4-methyl-5-phenyl-4H-1,2,4-triazole
• CAS NO: 116850-44-3
• Molecular Formula: C₁₀H₁₁N₃O₂S
• Molecular Weight: 237.28
• Mol File: 116850-44-3.mol

Chemical Properties

• Melting Point: 158-160 °C
• Boiling Point: 450.7°Cat760mmHg
• Flash Point: 226.4°C
• Appearance: /
• Density: 1.35g/cm³
• Vapor Pressure: 2.59E-08mmHg at 25°C
• Refractive Index: 1.637
• PKA: -1.34±0.10(Predicted)
• CAS DataBase Reference: 4-methyl-3-methylsulfonyl-5-phenyl-1,2,4-triazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-3-methylsulfonyl-5-phenyl-1,2,4-triazole(116850-44-3)
• EPA Substance Registry System: 4-methyl-3-methylsulfonyl-5-phenyl-1,2,4-triazole(116850-44-3)

Safety Data

• Hazardous Substances Data: 116850-44-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H11N3O2S/c1-13-9(8-6-4-3-5-7-8)11-12-10(13)16(2,14)15/h3-7H,1-2H3

Upstream product

• 38942-51-7 4-methyl-3-phenyl-1H-1,2,4-triazole-5(4H)-thione 
• 74-88-4 methyl iodide 
• 613-94-5 benzoic acid hydrazide 
• 58064-65-6 1-(phenyl)carbonyl-4-(methyl)thiosemicarbazide 
• 25812-76-4 4-methyl-3-methylsulfanyl-5-phenyl-4H-[1,2,4]triazole 

Downstream Products

• 130161-35-2 (4-Methyl-5-phenyl-4H-[1,2,4]triazol-3-yl)-phenyl-acetonitrile 

Relevant articles and documents

Triazolyl azabicyclo[3.1.0]hexanes: A class of potent and selective dopamine D3 receptor antagonists

Herein we report a detailed description of the structure-activity relationships for a novel series of "C-linked" 1,2,4- triazolylazabicyclo[3.1.0]hexanes. These derivatives are endowed with very high in vitro affinity and selectivity for the dopamine Dsu

Multi-cyclic compound and method of use

The present invention relates to chemical compounds having a general formula I wherein A, B, C1, C2, D, L1, L2 and R3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.

AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl and indazolyl; p is an integer ranging from 0 to 5; R1/s

5-Aryl-3-(alkylthio)-4H-1,2,4-triazoles as selective antagonists of strychnine-induced convulsions and potential antispastic agents

Selected examples from three series of isomeric (alkylthio)-1,2,4- triazoles were prepared and examined for anticonvulsant activity versus strychnine-, maximal-electroshock-, pentylenetetrazole-, and 3- mercaptopropionic-acid-induced seizures in mice. A n

3-aryl-5-alkylthio-4H-1,2,4-triazoles

This invention relates to novel sulfone and sulfoxide derivatives of 3-aryl-5-alkylthio-4H-1,2,4-triazoles and to the use of 3-aryl-5-alkylthio-, alkylsulfinyl- and alkylsulfonyl-4H-1,2,4-triazoles in the treatment of patients suffering from convulsant seizures.

3-aryl-5-alkylthio-4H-1,2,4-traizoles for treatment of hyperreflexia due to spinal trauma

This invention relates to the use of 3-aryl-5-alkylthio-4H-1,2,4-triazoles and the corresponding alkylsulfinyl- and alkylsulfonyl-4H-1,2,4-triazoles in the treatment of patients suffering from chronic hyperreflexia due to spinal trauma.

3-aryl-5-alkylthio-4H-1,2,4-triazoles

This invention relates to derivatives of 3-aryl-5-alkylthio-4H-1,2,4-triazoles, to their pharmacological properties and to their use as muscle relaxants, spasmolytics, anticonvulsants and anxiolytics.